Therapy News and Research

RSS

GE, MSKCC launch colon cancer study

A team of scientists at GE Global Research, the technology development arm for the GE, has launched a study with Memorial Sloan-Kettering Cancer Center, (MSKCC) one of the world's premier cancer centers, to better understand the early stages of colon cancer. The goal is to yield new insights that improve treatment selection and outcomes for cancer patients in the future.

22 Jul 2010

Elan total revenue increases 10% to $579.4 million for first half of 2010

Elan Corporation, plc today reported its second quarter and first half 2010 financial results.

22 Jul 2010

Smoking cessation effectively alter subgingival microbiome in patients on periodontal therapy: Study

Patients with chronic gum disease who quit smoking in addition to undergoing nonsurgical therapy not only demonstrated a lower abundance of harmful oral pathogens, but also an increase in health-associated bacteria. The researchers from The Ohio State University, Columbus Ohio, and Newcastle University, United Kingdom report their findings in the July 2010 issue of the Journal of Clinical Microbiology.

22 Jul 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010. The Company reported total revenue of $164.4 million for the quarter ended June 30, 2010, which includes net product sales of $162.5 million. Net loss, excluding a restructuring charge of $3.4 million, was $40.8 million, or $0.28 per share.

22 Jul 2010

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.

22 Jul 2010

BSD provides additional information to FDA for 510(k) submission of MicroThermX Microwave Ablation System

BSD Medical Corporation today announced that it has provided the additional information requested by the U.S. Food and Drug Administration (FDA) for review of the 510(k) submission the Company filed for premarket clearance of the Company's Phase II MicroThermX® Microwave Ablation System (MTX-180) for ablation of soft tissue.

22 Jul 2010

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

The VA Maryland Health Care System participated in a landmark national study of more than 10,251 high-risk diabetic adults across the nation, testing if three complementary treatment strategies can reduce the high rate of heart disease and stroke associated with type 2 diabetes and if these treatment strategies can also slow the progression of eye disease associated with diabetes, the leading cause of blindness in working-age Americans.

22 Jul 2010

Valproic acid halts vision loss in patients with retinitis pigmentosa

Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.

22 Jul 2010

Experts outline three elements necessary for ending HIV/AIDS pandemic

According to a new editorial, the world can control and ultimately end the HIV/AIDS pandemic through a three-pronged strategy

22 Jul 2010

Surgery & physical therapy equally effective in knee ligament tears: study

A new study released this Wednesday compared intense physical therapy with surgery in common knee ligament injury and found that both techniques had similar outcomes.

21 Jul 2010

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

According to a Food and Drug Administration (FDA) advisory committee’s (The Oncology Drugs Advisory Committee, or ODAC) recommendation this Tuesday, the marketing approval of the popular breast cancer drug, Avastin or Bevacizumab should be withdrawn.

21 Jul 2010

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme Corp. today reported that second-quarter revenue was $1.08 billion, compared with $1.23 billion in the same period last year, reflecting limited shipments of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) due to product supply constraints in 2010. The company expects to be able to increase shipments of Cerezyme and Fabrazyme during the second half of the year.

21 Jul 2010

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572) into Phase III clinical trials. '572 will be the only once-daily, unboosted integrase inhibitor in Phase III clinical development.

21 Jul 2010

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

Concentric Medical announces treatment of first stroke patient with Merci Retriever

Concentric Medical, Inc., the global leader in devices for clot removal in acute ischemic stroke patients, today announced the treatment of the first patient in Japan with the Merci Retriever. The Merci Retriever is a catheter-based medical device that stroke centers use to remove blood clots from the brains of patients suffering an acute ischemic stroke.

21 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

Clinical research updates on interventional cardiology techniques that affect patient care

TCT 2010 will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients' quality of life

Results from the landmark AIDS Treatment for Life International Survey, a multi-country survey of more than 2,000 people living with HIV/AIDS, revealed a significant gap in patient-physician dialogue about critical health-related conditions that may negatively impact patients' overall long-term health, quality of life, and treatment outcomes.

21 Jul 2010

Experts urge global leaders to commit $20 billion to Global Fund to Fight AIDS, Tuberculosis and Malaria

Scientists, practitioners and advocates from around the world today made a united call for global leaders to commit at least $US20 billion to the Global Fund to Fight AIDS, Tuberculosis and Malaria at its upcoming replenishment meeting in October. Because the level of replenishment committed at the meeting will determine the Global Fund's grant levels for 2011-2013, the meeting is widely viewed as the critical next step towards universal access to HIV prevention, treatment, care and support.

21 Jul 2010

Therapy News and Research

GE, MSKCC launch colon cancer study

Elan total revenue increases 10% to $579.4 million for first half of 2010

Smoking cessation effectively alter subgingival microbiome in patients on periodontal therapy: Study

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Onyx begins Phase 3 trial of carfilzomib in combination with lenalidomide, dexamethasone for relapsed myeloma

BSD provides additional information to FDA for 510(k) submission of MicroThermX Microwave Ablation System

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Valproic acid halts vision loss in patients with retinitis pigmentosa

Experts outline three elements necessary for ending HIV/AIDS pandemic

Surgery & physical therapy equally effective in knee ligament tears: study

Avastin – breast cancer drug, fails to pass the FDA advisory panel vote on efficacy

Genzyme second-quarter revenue decreases to $1.08 billion

Shionogi-ViiV Healthcare to advance '572 inhibitor into Phase III clinical trials

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

Concentric Medical announces treatment of first stroke patient with Merci Retriever

Health Canada grants Osiris Priority Review for Prochymal NDS

Clinical research updates on interventional cardiology techniques that affect patient care

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients' quality of life

Experts urge global leaders to commit $20 billion to Global Fund to Fight AIDS, Tuberculosis and Malaria

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News